Chair(s): Corrado Angelini (Italy), Marianne de Visser (Netherlands)

• TC 1.1: Clinical phenotypes and management of patients with hyperCKemia and statin myopathy - Marianne de Visser (Netherlands)
• TC 1.2: How to diagnose a patient with hyperCKemia - Sabrina Sacconi (France)
• TC 1.3: Metabolic myopathies with hyperCKemia or cramps - Corrado Angelini (Italy)
• TC 1.4: Diagnostic approach and guidelines for oligosymptomatic hyperCKemia - Thedore Kyriakides (Cyprus)

Chair(s): William (Bill) Phillips (Australia), Hanns Lochmüller (UK)

• TC 2.1: Introduction to structure & function, mechanisms of NMJ development and effects of autoantibodies - William (Bill) Phillips (Australia)
• TC 2.2: Neurophysiology - Clark Slater (UK)
• TC 2.3: Presynaptic receptors - Ana Maria Sebastião (Portugal)
• TC 2.4: Diseases involving impairment and loss of neuromuscular connections - Hanns Lochmüller (UK)

Chair(s): Michaela Auer-Grumbach (Austria), Davide Pareyson (Italy)

• TC 3.1: CMT Neuropathies in the elderly - Michaela Auer-Grumbach (Austria)
• TC 3.2: Essential clues to early recognition of amyloid neuropathies - Davide Pareyson (Italy)
• TC 3.4: Neuropathic manifestations in porphyria - James Dyck (USA)
• TC 3.3: Sensory and Autonomic Hereditary Neuropathies - Max Hilz (Germany)

Chair(s): Günther Bernert (Austria), James Dowling (Canada)

• TC 4.1: Introduction: Epidemiology and Differential Diagnosis - Günther Bernert (Austria)
• TC 4.2: The Muscle Biopsy in the “Next-Gen-Era”: snows of yesteryears? - Reginald Bittner (Austria)
• TC 4.3: Floppy infant syndrome and the role of “next gen” - James Dowling (Canada)
• TC 4.4: What you may miss without EMG - Matthew Pitt (UK)

Chair(s): Wolfgang Löscher (Austria), Nens van Alfen (Netherlands)

• TC 5.0: EDX and Sonography – A Critical Appraisal – Wolfgang Löscher (Austria)
• TC 5.1: Entrapment syndromes in the upper extremity - Electrophysiology - Christian Bischoff (Germany)
• TC 5.2: Entrapment syndromes in the upper extremity - Sonography - Nens van Alfen (Netherlands)
• TC 5.3: Entrapment syndromes in the lower extremity - Electrophysiology - Simon Podnar (Slovenia)
• TC 5.4: Entrapment syndromes in the lower extremity - Sonography - Alexander Grimm (Germany)
• TC 5.5: Sonography Hands On - Nens van Alfen (Netherlands) & Alexander Grimm (Germany)

Chair(s): Richard Barohn (USA), Mazen Dimachkie (USA)

• TC 6.1: Pattern recognition approach to muscle disorders - Richard Barohn (USA)
• TC 6.2: Laboratory approach to muscle disorders - Mazen Dimachkie (USA)
• TC 6.3: Genetic approach to muscle disorders - Tahseen Mozaffar (USA)
• TC 6.4: Approach to translational research and clinical trials in muscle disease - Michael Hanna (UK)

Chair(s): Albert Ludolph (Germany), Dorothée Lulé (Germany)

• TC 7.1: How do we discuss the genetic implications with ALS - Ryuji Kaji (Japan)
• TC 7.2: Cognitive change – recognition and management - Albert Ludolph (Germany)
• TC 7.3: Breaking the news of the diagnosis - Dorothée Lulé (Germany)
• TC 7.4: The role of multidisciplinary care in ALS - Christopher McDermott (UK)

Chair(s): Peter Van den Bergh (Belgium), Ingemar Merkies (Netherlands)

• TC 8.1: MRI and US in the diagnosis of neuropathy - Stephan Goedee (Netherlands)
• TC 8.2: Skin biopsy: not just for diagnosis - Grazia Devigili (Italy)
• TC 8.3: Outcome measures in neuropathy - Ingemar Merkies (Netherlands)
• TC 8.4: Role of electrophysiology in the characterization and diagnosis of neuropathies: new insights - Peter Van den Bergh (Belgium)

Chair(s): Kanneboyina Nagaraju (USA), Raffaella Willmann (Switzerland), Volker Straub (UK)

• Introduction - Volker Straub (UK)

• TC 9.1: Requirements and pitfalls for small molecules - Mike Kelly (USA)
• TC 9.2: Requirements and pitfalls for gene therapy - Isabelle Richard (France)
• TC 9.3: Requirements and pitfalls for stem cells - Miranda Grounds (Australia)

• TC 9.4: Preclinical trial design - Annamaria De Luca (Italy)
• TC 9.5: Statistical power evaluation - Heather Gordish-Dressman (USA)
• TC 9.6: Data interpretation, translational meaning - Annamaria De Luca (Italy)

• TC 9.7: Regulatory requirements - Didier Caizergues (France)
• TC 9.8: Clinical trial readiness - Kathryn Wagner (USA)
• TC 9.9: Care aspects in clinical trial planning - Anna Mayhew (UK)
• TC 9.10: Patient perspective - Elizabeth Vroom (Netherlands)
• TC 9.11: Business model - Cristina Csimma (USA)

Q&A

Chair(s): Walter Struhal, (Austria), Anne Pavy-Le Traon (France), J.G. Van Dijk (Netherlands), G. K. Wenning (Austria)

I – Health and disease
• Chair: Walter Struhal, AT
• 13:00 TC 10.1: ANS: THE INTERFACE BETWEEN OUTER AND INNER WORLD - Heinz Lahrmann, AT
• 13:15 TC 10.2: AUTONOMIC DISORDERS: WHAT GOES WRONG – Heinz Lahrmann, AT
• 13:30 HANDS-ON DISCUSSION

II – Diagnostic tools
• Chair: Anne Pavy-Le Traon, FR
• 13:40 TC 10.3: CARDIOVASCULAR AUTONOMIC FUNCTION TESTS AND ABPM – Giovanna Calandra-Buonaura, IT
• 13:55 TC 10.4: NEUROENDOCRINE AND NUCLEAR AUTONOMIC FUNCTION TESTS – Camilla Rocchi, IT
• 14:10 HANDS-ON DISCUSSION
• 14:20 TC 10.5: PRACTICAL SESSION: HOW TO PERFORM A CARDIOVASCULAR AUTONOMIC FUNCTION TEST– Walter Struhal, AT

15:05 NETWORKING BREAK

III – Bedside approach to ANS disorders
• Chair: J.Gert Van Dijk, NL
• 15:20 TC 10.6: AUTONOMIC HISTORY TAKING: YOU NEED TO KNOW WHAT YOU’RE LOOKING FOR – Anne Pavy-Le Traon, FR
• 15:35 TC 10.7: SYMPTOMS & SIGNS OF SYNCOPE IN THE CONTEXT OF TRANSIENT LOSS OF CONSCIOUSNESS– Roland Thijs, NL
• 15:50 TC 10.8: AUTONOMIC SYNDROMES: HOW TO PUT THE PIECES OF THE JIGSAW TOGETHER – Eva Lenzenweger, AT
• 16:05 HANDS-ON DISCUSSION

IV – Management of ANS disorders
• Chair: Gregor K. Wenning, AT
• 16:15 TC 10.9: SYNCOPE AND PSEUDOSYNCOPE – J. Gert Van Dijk, NL
• 16:30 TC 10.10: EBM TREATMENT OF ORTHOSTATIC HYPOTENSION AND RELATED SYMPTOMS – Gregor K. Wenning, AT
• 16:45 HANDS-ON DISCUSSION
 
• 16:55 TC 10.11: EVALUATION FORMS AND CONCLUDING REMARKS

To see the full EFAS 2018 program, click here.

Chair(s): Stefan Meng (Austria), Daniel Truong (USA)

• Welcome and basic anatomy and intervention tactics
• Nerve Part 1.1: Hands-on Ultrasound assessment of local, perineural anatomy
• Nerve Part 1.2: Ultrasound guided injections in anatomic specimen
• Muscle: Practical muscle botulinum toxin injection course – Daniel Truong (USA)
• Nerve Part 2.1: Inspections of prepared specimens from Nerve Part 1: anatomical topology, injection fluid distribution
• Nerve Part 2.2: New nerve ultrasound injections in anatomic specimen

To see the full course details, click here.

Chair(s): Wolfgang Grisold (Austria)

• • 13.10 - 13.30 AUS DER SICHT DES PATIENTEN: ERKRANKUNGEN DES NEUROMUSKULAREN ÜBERGANGES (MYASTHENIA GRAVIS) - Evelyn Suritsch, AT
  • 13.30 - 13.50 MUSKELERKRANKUNGEN BEI KINDERN, NEUE THERAPIEN - Guenther Bernert, AT
  • 13:50 - 14:10 MUSKELERKRANKUNGEN BEI ERWACHSENEN - Julia Wanschitz, AT
  • 14:10 - 14:30 POLYNEUROPATHIEN - Wolfgang Löscher, AT
  • 15:00 - 15:20 POLYNEUROPATHIEN - FOKUS DIABETES MELLITUS - Anna Grisold, AT
  • 15:20 - 15:40 "DIE EINGESCHLAFENE HAND“ - Elisabeth Lindeck-Pozza, AT
  • 15:40 - 16:00 ERKRANKUNGEN DES NEUROMUSKULAREN UBERGANGES (MYASTHENIA GRAVIS) - Raffi Topakian, AT
  • 16:00 - 16:20 ERKRANKUNGEN DES AUTONOMEN NERVENSYSTEMS - Walter Struhal, AT
  • 16:20 - 16:40 AMYOTROPHE LATERAL SKLEROSE (ALS) - Heinz Lahrmann, AT

Chair(s): Walter Struhal (Austria), Max Hilz, (Germany), Alessandra Fanciulli (Austria), Pietro Guaraldi (Italy), J.Gert Van Dijk (Netherlands), Roland Thijs (Netherlands), Anne Pavy-Le Traon (France), Mario Habek (Croatia)

Plenary Session I) Peripheral autonomic neuropathies
• Chairs: Max Hilz, DE & Walter Struhal, AT
• 08:00 PL 1: DIABETIC AUTONOMIC NEUROPATHY - Roy Freeman, US
• 08:30 PL 2: AUTONOMIC DYSFUNCTION IN GBS - Max Hilz, DE
• 08:50 PL 3: ANS AND AMYLOID - Teresa Coelho, PT

Scientific Session I:
• Chairs: Max Hilz, DE & Walter Struhal, AT
• 09:10 SS 1: AUTOIMMUNE AUTONOMIC GANGLIONOPATHY: THE NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY, QUEEN SQUARE EXPERIENCE (Abstract ID: 981) - Shiwen Koay, GB
• 09:20 SS 2: MICRONEUROGRAPHIC EVIDENCE AGAINST BAROREFLEX BLUNTING WITH PERIPHERAL CHEMOREFLEX ACTIVATION IN HUMANS (Abstract ID: 889) - Karsten Heusser, DE
• 09:30 SS 3: THE NATURAL HISTORY OF A COHORT OF ISOLATED AUTONOMIC FAILURE PATIENTS (Abstract ID: 946) - Pietro Guaraldi, IT
• 09:35 SS 4: ORTHOSTATIC HYPERTENSION: A RARE KNOWN DYSAUTONOMIA (Abstract ID: 913) - Alvaro Petersen, MX
• 09:40 SS 5: HOW TO OVERCOME POST-OPERATIVE ILEUS IN PERITONITS PATIENS (Abstract ID: 879) - Peter Lechner, AT

09:50 NETWORKING BREAK

Plenary Session II) Neurodegeneration & ANS
• Chairs: Alessandra Fanciulli, AT & Pietro Guaraldi, IT
• 10:40 PL 4: PAF-MSA-PARKINSON HOW TO DIFFERENTIATE, HOW TO CONFUSE, SIMILARITIES AND SPECIFICS - Gregor K. Wenning, AT
• 11:00 PL 5: LINKS FROM PERIPHERY TO THE BRAIN - Alessandra Fanciulli, AT
• 11:20 PL 6: SLEEP DISORDERS & ANS - Pietro Guaraldi, IT
• 11:40 PL 7: AUTONOMIC DYSFUNCTION IN DEMENTIA - Walter Struhal, AT

Scientific Session II:
• Chairs: Alessandra Fanciulli, AT & Pietro Guaraldi, IT
• 12:00 SS 6: AUTONOMIC DYSFUNCTION IN THE INITIAL MOTOR STAGE OF PARKINSON’S DISEASE: A 3-YEAR LONGITUDINAL STUDY (Abstract ID: 897) - Iva Stankovic, RS
• 12:05 SS 7: ACQUIRED IDIOPATHIC GENERALIZED ANHIDROSIS IN A YOUNG AUSTRIAN PATIENT (Abstract ID: 890) - Gerald Exler, AT

12:10 NETWORKING BREAK

12:55 GUIDED POSTER WALK

Plenary Session III) TLOC, Brain injury and ANS sequelae
• Chairs: J.Gert Van Dijk, NL & Roland Thijs, NL
• 13:45 PL 8: Differential diagnosis - J. Gert Van Dijk, NL
• 14:05 PL 9: Autonomic Dysfunction in epilepsy - Roland Thijs, NL
• 14:25 PL 10: STROKE AND ANS - Max Hilz, DE
• 14:45 PL 11: SYNCOPEDIA: TRAINING A NEW GENERATION OF SYNCOPE SPECIALISTS - Jelle De Jong, NL

Scientific Session III:
• Chairs: J.Gert Van Dijk, NL & Roland Thijs, NL
• 15:05 SS 8: MUTUALLY EXCLUSIVE CRITERIA FOR NEUROGENIC ORTHOSTATIC HYPOTENSION AND VASOVAGAL SYNCOPE DURING TILT-TABLE TESTING (Abstract ID: 400) - Maryam Ghariq, NL
• 15:10 SS 9: HEART RATE VARIABILITY IS ASSOCIATED WITH OUTCOME IN SPONTANEOUS INTRACEREBRAL HEMORRHAGE (Abstract ID: 893) - Marek Sykora, AT

15:15 NETWORKING BREAK

Plenary Session IV) Autonomic Nervous system and Fatigue Background and Management
• Chairs: Anne Pavy-Le Traon, FR & Mario Habek, HR
• 15:45 PL 12: AUTONOMIC NERVOUS SYSTEM IN SIMULATED AND REAL WEIGHTLESSNESS - Anne Pavy-Le Traon, FR
• 16:05 PL 13: PROGNOSTIC AUTONOMIC BIOMARKERS - Jean-Michel Senard, FR
• 16:25 PL 14: FATIGUE AND AUTONOMIC NERVOUS SYSTEM DYSFUNCTION IN PEOPLE WITH MULTIPLE SCLEROSIS - Mario Habek, HR
• 16:45 PL 15: GASTRIC DYSFUNCTION - Heinz Zoller, AT

Scientific Session IV:
• Chairs: Anne Pavy-Le Traon, FR & Mario Habek, HR
• 17:05 SS 10: UROFLOWMETRY SHOWS SLIGHTLY IMPAIRED AUTONOMIC BLADDER FUNCTION IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (Abstract ID: 887) - Ruihao Wang, DE

17:15 CLOSING REMARKS AND POSTER PRIZE

Please click here to view the EFAS 2018 Poster Listing: POSTER LISTING

To see the full EFAS 2018 program, click here.

Chair(s): Wolfgang Grisold (Austria), John England (USA)

• PL 1.1: Pathomechanisms - Volker Straub (UK)
• PL 1.2: Inflammatory mechanisms - Andrew Mammen (USA)
• PL 1.3: Genetics / Epigenetics - Hanns Lochmüller (Germany)

Chair(s): Marianne de Visser (Netherlands), Kanneboyina Nagaraju (USA)

• SS 1.1: Treatment strategies in GNE myopathy - Zohar Argov (Israel)
• SS 1.2: Update of RNA-Based NMD therapies - Kanneboyina Nagaraju (USA)
• SS 1.3: Progress in the treatment of idiopathic inflammatory myopathies? - Marianne de Visser (Netherlands)

Chair(s): Anthony Windebank (USA), Heinz Redl (Austria)

• SS 2.1: Tissue Engineering Strategies for Repair of Peripheral Nerve - Anthony Windebank (USA)
• SS 2.2: Use of physical methods in nerve regeneration - Thomas Hausner (Austria)
• SS 2.3: New developments in conduits – David Hercher (Austria)

Chair(s): Bruno Giometto (Italy), Andrew Mammen (USA)

• SS 3.1: The role of HU proteins in the development of paraneoplastic neuropathies - Bruno Giometto (Italy)
• SS 3.2: Physiopathology of paraneoplastic ganglionopathies - Romana Hoeftberger (Austria)
• SS 3.3: Paraneoplastic muscle disorders - Andrew Mammen (USA)
• SS 3.4: Lambert-Eaton-Syndrome (LEMS) - Jan Verschuuren (Netherlands)

Chair(s): Antonio Toscano (Italy), Bjarne Udd (Finland)

• SS 4.1: Update on clinical aspects of Glycogen storage disorders - Antonio Toscano (Italy)
• SS 4.2: Novel entities in congenital myopathies of adult onset - Baziel van Engelen (Netherlands)
• SS 4.3: New phenotypes in titin defects - Bjarne Udd (Finland)

Chair(s): Anthony Windebank (USA), Tatjana Paternostro-Sluga (Austria)

• WS 1.1: Chemotherapy induced PNP - Anthony Windebank (USA)
• WS 1.2: Iatrogenic mononeuropathies after surgery and trauma - Tatjana Paternostro-Sluga (Austria)
• WS 1.3: Case Report - Anthony Windebank (USA) & Tatjana Paternostro-Sluga (Austria)

Chair(s): Günther Bernert (Austria), James Dowling (Canada)

• SS 5.1: Introduction: Standards of Care: what we have learned from long term-management in children with NMD's - Günther Bernert (Austria)
• SS 5.2: Future of AAV-based gene therapy approaches for NMDs - Thomas Voit (UK)
• SS 5.3: New Treatments in Paediatric NMD's: Fake or Fact? - Eugenio Mercuri (Italy)
• SS 5.4: Transition from paediatric into adult care: a long way to go? - Thomas Serjensen (Sweden)

Chair(s): Zohar Argov (Israel), Mayana Zatz (Brazil)

• OA 1.1: Stem cells as tools for research and therapy in neuromuscular disorders - Rita Perlingeiro (USA)
• OA 1.2: Stem cells in muscular dystrophies - Mayana Zatz (Brazil)
• OA 1.3: Stem cells in ALS - Dimitrios Karussis (Israel)

Chair(s): Ahmet Hoke (USA), Guido Cavaletti (Italy)

• SS 6.1: General principles/clinical aspects - Nathan Staff (USA)
• SS 6.2: Basic mechanisms: Axonal degeneration and chemotherapy-induced peripheral neuropathy - Ahmet Hoke (USA)
• SS 6.3: Animal models of chemotherapy-induced peripheral neuropathy - Guido Cavaletti (Italy)

Chair(s): George Padberg (Netherlands), Nicol Voermans (Netherlands)

• WS 2.1: DUX4, its role in development and muscle disease - Stephen Tapscott (USA)
• WS 2.2: Trials readiness in FSHD: clinical, imaging and other biomarkers - Jeffrey Statland (USA)
• WS 2.3: FSHD's changing landscape and future perspectives - George Padberg (Netherlands)

Chair(s): David Oliver (UK), Chris McDermott (UK)

• WS 3.1: The role of palliative care – early involvement or end of life care? - David Oliver (UK)
• WS 3.2: The role of the multidisciplinary team in NMD – the evidence from ALS - Christopher McDermott (UK)
• WS 3.3: The recognition of the end of life phase in NMD – the support of patients, families and professionals - Stefan Lorenzl (Austria)
• WS 3.4: Integrating palliative care into service for ALS patients: experiences from Russia - Lev Brylev (Russia)

Chair(s): Anthony Amato (USA), Jasper M. Morrow (UK)

• WS 4.1: Update on Histopathological Features of Inflammatory Myopathies - Anthony Amato (USA)
• WS 4.2: Update on Myositis Specific Autoantibodies - Discussion on utility of MSAs in diagnosis and prognosis - Andrew Mammen (USA)
• WS 4.3: Update on Utility of Skeletal Muscle MRI and Ultrasound - Jasper M. Morrow (UK)

Chair(s): TBD

• Presenting Topic Group: 1
• Please click the button to view the ICNMD2018 Poster Listing: POSTER LISTING

• Please click here to see detailed Information for Poster Presenters.

Chair(s): Mary Reilly (UK), Eva Feldman (USA)

• PL 2.1: Inherited neuropathies: from genes to clinical phenotype - Mary Reilly (UK)
• PL 2.2: Immune mediated neuropathies: an expanding field of treatable neuropathies - Peter van Doorn (Netherlands)
• PL 2.3: Advances in the treatment of peripheral neuropathy - David Cornblath (USA)

Chair(s): Vincent Timmermann (Belgium), Michael Sereda (Germany)

• SS 7.1: New genes and new mechanisms in inherited neuropathies - Vincent Timmermann (Belgium)
• SS 7.2: Therapeutic options in CMT - Michael Sereda (Germany)
• SS 7.3: Familial amyloid neuropathies: a treatable genetic neuropathy - Davide Pareyson (Italy)

Chair(s): Wolfgang Grisold (Austria), Nazdha Birouk (Morocco)

• SS 8.1: Cranial nerves: within and out of the skull, incl. Angiosoma - Wolfgang Grisold (Austria)
• SS 8.2: Infectious and Inflammatory Cranial nerve lesions - Nazha Birouk (Morocco)
• SS 8.3: Painful cranial nerve lesions - Frank Thömke (Germany)
• SS 8.4: Paroxysmal dysfunctions - Friedrich Zimprich (Austria)

Chair(s): Walter Struhal (Austria), John England (USA)

• SS 9.1: Proteinopathies (The Autonomic View) - Gregor K. Wenning (Austria)
• SS 9.2: Proteinopathies (The Neuromuscular View) - Walter Struhal (Austria)
• SS 9.3: Hereditary Neuropathies (The Autonomic View) - Max Hilz (Germany)
• SS 9.4: Hereditary Neuropathies (The Neuromuscular View) - Michaela Auer-Grumbach (Austria)
• SS 9.5: Metabolic ANS Disease (Diabetes And Liver) (The Autonomic View) - Roy Freeman (United States)
• SS 9.6: Metabolic ANS Disease (Diabetes And Liver) (The Neuromuscular View) - Paola Sandroni (United States)

Chair(s): Eva Feldman (USA), Vera Bril (Canada)

• SS 10.1: 2017 ADA Position Statement on Diabetic Neuropathy: Does it change your practice? - Vera Bril (Canada)
• SS 10.2: Scientific Discovery Leads to Clinical Trials in Diabetic Neuropathy - James Russell (USA)
• SS 10.3: Painful Diabetic Neuropathy: A Management Centered Approach - Eva Feldman (USA)

Chair(s): Eduardo Nobile-Orazio (Italy), Jean-Marc Léger (France)

• WS 5.1: Diagnosis and treatment of CIDP: lesson from the databases - Eduardo Nobile-Orazio (Italy)
• WS 5.2: Paraproteinemic neuropathies: when and how to treat - Jean-Marc Léger (France)
• WS 5.3: POEMS syndrome: from diagnosis to therapy - Michelle Mauermann (USA)

Chair(s): Stefan Meng (Austria), Chieh-Han John Tzou (Austria)

• WS 6.1: Ultrasound in Cranial Nerves - Stefan Meng (Austria)
• WS 6.2: Clinical and microsurgical significance of cranial nerve visualization - Andres Rodriguez (Sweden)
• WS 6.3: High resolution MRI of cranial nerves - Jennifer Kollmer (Germany)

Chair(s): Kathy Oliver (UK), Stefan Oberndorfer (Austria)

• SS 11.4: How can outcomes of clinical studies be translated for patients - Angela Genge (Canada)
• SS 11.2: Approach to Patient-Centered Outcomes Research - Richard Barohn (USA)
• SS 11.3: The Patient Voice in Myasthenia Gravis Trials- PCORI, CER, and more alphabet soup - Pushpa Narayanaswami (USA)
• SS 11.1: James Lind Alliance Priority Setting Partnership in Neuro-Oncology (research priorities) - Kathy Oliver (UK)

Chair(s): Zohar Argov (Israel), Antonio Toscano (Italy)

• OA 2.1: Neuromuscular disorders with dysphagia: an outline - Marianne de Visser (Netherlands)
• OA 2.2: How to assess and manage dysphagia - Zohar Argov (Israel)
• OA 2.3: Ethical issues in dysphagia treatments - David Oliver (UK)

Chair(s): Hugh Willison (UK), Angelo Schenone (Italy)

• SS 12.1: Pathophysiology of the Node of Ranvier - Antonino Uncini (Italy)
• SS 12.2: New pathogenetic mechanisms underlying immune neuropathies - Hugh Willison (UK)
• SS 12.3: Antibodies to the node of Ranvier in CIDP: a new clue to therapy - Louis Querol (Spain)

Chair(s): Ioannis Gioulbasanis (Greece), Christine Marosi (Austria)

• WS 7.1: Cachexia and late effects of cancer - Ioannis Gioulbasanis (Greece)
• WS 7.2: Sarcopenia - Alan Pestronk (USA)
• WS 7.3: Outline on myopathies / neuromuscular complications associated with cancer, incl. steroid myopathy - Anthony Amato (USA)
• WS 7.4: Cancer rehabilitation - Christine Marosi (Austria)

Chair(s): Andreas Steck (Switzerland), Ingemar Merkies (Netherlands)

• WS 8.1: Spectrum of paraproteinemic neuropathies - Eduardo Nobile-Orazio (Italy)
• WS 8.2: Anti-MAG neuropathy: current and novel treatments - Andreas Steck (Switzerland)
• WS 8.3: Creating proper outcome measures - Ingemar Merkies (Netherlands)

Chair(s): N/A

• NEUROPATHIES IN AFRICA - Riadh Gouider (Tunisia)
• HIV-ASSOCIATED NEUROMUSCULAR MANIFESTATIONS: EXPERIENCE FROM CAPE TOWN - Jeannine Heckmann (South Africa)

Chair(s): George Padberg (Netherlands), Baziel van Engelen (Netherlands)

• Introduction about the ENMC - Ellen Sterrenburg (Netherlands)
• Why opt for an ENMC workshop? - George Padberg (Netherlands) & Baziel van Engelen (Netherlands)
• The impact of 25 years ENMC workshops - Raffaella Willmann (Switzerland)
• Charcot-Marie-Tooth Disease at ENMC workshops - Mary Reilly (UK)
• Translational research workshop - Kanneboyina Nagaraju (USA)
• Management of ventilation problems in patients with neuromuscular conditions - Michel Toussaint (Belgium)
• The position of neuromuscular patients in Shared Decision Making - Anna Ambrosini (Italy)
• Questions and conclusion of the ENMC symposium- George Padberg (Netherlands)

Chair(s): TBD

• Presenting Topic Groups: 3, 5, 6, 9
• Please click the button to view the ICNMD2018 Poster Listing: POSTER LISTING

• Please click here to see detailed Information for Poster Presenters.

Chair(s): Vera Bril (Canada), Claude Desnuelle (France)

• PL 3.1: Emerging therapies for Motor Neurone Diseases - Peter Andersen (Sweden)
• PL 3.2: Clinical concept of ALS - Leonard Van den Berg (Netherlands)
• PL 3.3: Ethical issues - David Oliver (UK)

Chair(s): Peter Andersen (Sweden), Nathalie Goemans (Belgium)

• SS 13.1: Overview – drug treatment for SMA - Janbernd Kirschner (Germany)
• SS 13.2: Treatments to improve survival of motor neurons - Anne-Marie Hübers (Germany)
• SS 13.3: Splicing modification for SMA - Nathalie Goemans (Belgium)
• SS 13.4: Gene therapy for SMA - Arthur Burghes (USA)

Chair(s): Stefan Meng (Austria), Udo Zifko (Austria)

• SS 14.1: MR Neurography: New approaches and techniques for diagnosing mononeuropathies - Jennifer Kollmer (Germany)
• SS 14.2: New ultrasensitive Ultrasound methods - Stefan Meng (Austria)
• SS 14.3: Ultra high vs. low field MR neurography: the advantages and pitfalls of 7T MRI - Sigrun Roat (Austria)

Chair(s): David Bennett (UK), Claudia Sommer (Germany)

• SS 15.1: Changes in the nodal complex in painful neuropathy - Claudia Sommer (Germany)
• SS 15.2: The use of nerve excitability testing in understanding ion channel dysfunction in neuropathy - Matthew Kiernan (Australia)
• SS 15.3: Human pain channelopathies - David Bennett (UK)

Chair(s): Marianne de Visser (Netherlands), Esther Hobson (UK)

• SS 16.1: NIV and ALS - Marianne de Visser (Netherlands)
• SS 16.2: Nutrition and ALS - Esther Hobson (UK)
• SS 16.3: Nutrition NIV and cognition in ALS - Vincenzo Silani (Italy)

Chair(s): Wolfgang Grisold (Austria), Michelle Mauermann (USA)

• SS 17.1: Neurofibromatosis - Katharina Wimmer (Austria)
• SS 17.2: Peripheral nerve tumors - Gelareh Zadeh (Canada)
• SS 17.3: Perineuroma - Michelle Mauermann (USA)
• SS 17.4: Cancer and peripheral nerves - Wolfgang Grisold (Austria)

Chair(s): Thomas Hausner (Austria), Brian Callaghan (USA)

• WS 9.1: Nerve fibre transfer versus nerve reconstruction - Robert Schmidhammer (Austria)
• WS 9.2: Nerve regeneration - Ahmet Hoke (USA)
• WS 9.3: Brain plasticity in nerve regeneration - Thomas Hausner (USA)

Chair(s): Matthew Kiernan (Australia), Alan Pestronk (USA)

• SS 18.1: MND: Therapeutic landscapes - Matthew Kiernan (Australia)
• SS 18.2: Treatment Strategies for Hereditary ALS - Tim Miller (USA)
• SS 18.3: Diagnosis and Treatment of Motor neuropathies - Alan Pestronk (USA)

Chair(s): Zohar Argov (Austria), Corrado Angelini (Italy)

• OA 3.1: Impact and evolution of cognitive impairment in muscular dystrophies - Corrado Angelini (Italy)
• OA 3.2: Brain imaging techniques for the neuromuscular patients - Nicola de Stefano (Italy)
• OA 3.3: The gap between cognitive assessment and brain imaging: lessons from DMD - Erik Niks (Netherlands)

Chair(s): Davide Pareyson (Italy), Teresa Coelho (Portugal)

• WS 10.1: How Transthyretin becomes toxic - Laura Obici (Italy)
• WS 10.2: Challenges in diagnosing and monitoring ATTR amyloidosis - Davide Pareyson (Italy)
• WS 10.3: The novel scenario of ATTR amyloidosis treatment - Teresa Coelho (Portugal)

Chair(s): Steven Lewis (USA), Nathan Staff (USA)

• WS 11.1: Vitamin deficiencies and neuropathy - Carrie Grouse (USA)
• WS 11.2: Mineral deficiencies and neuropathy - Steven Lewis (USA)
• WS 11.3: Vitamin and mineral toxicities and neuropathy - Nathan Staff (USA)

Chair(s): Wolfgang Löscher (Austria), Aleš Pražnikar (Slovenia)

• SS 19.1: Distal hereditary motor neuropathies (dHMN) - Mary Reilly (UK)
• SS 19.2: Distal Myopathies - Anthony Amato (USA)
• SS 19.3: Acquired distal motor syndromes - Matthew Kiernan (Australia)

Chair(s): Wolfgang Grisold (Austria), James Dyck (USA)

• WS 13.1: Cranial nerves - Wolfgang Grisold (Austria)
• WS 13.2: Peripheral nerve lymphoma - James Dyck (USA)
• WS 13.3: Cancer-associated Myositis - Yves Allenbach (France)

Chair(s): TBD

• Presenting Topic Groups: 2, 4, 7, 8
• Please click the button to view the ICNMD2018 Poster Listing: POSTER LISTING

• Please click here to see detailed Information for Poster Presenters.

Chair(s): Julia Wanschitz (Austria), Juan Jesús Vílchez Padilla (Spain)

• PL 4.1: Physiology and structure - Steve Burden (USA)
• PL 4.2: Congenital Myasthenic Syndromes - New genes and better treatments / antibodies (Virtual Presentation) - Kinji Ohno (Japan)
• PL 4.3: Autoimmunity - Angela Vincent (UK)

Chair(s): Gil Wolfe (USA), Wolfgang Löscher (Austria)

• SS 20.1: Evolution of monoclonal Ab treatment approaches in MG - Gil Wolfe (USA)
• SS 20.2: Other novel treatment approaches: 3, 4 DAP, alpha fetoprotein, exercise - Anna Punga (Sweden)
• SS 20.3: Overview of treatment guidelines: going forward - Gil Wolfe (USA)

Chair(s): John England (USA), Gerard Said (France)

• SS 21.1: Neurological complications of Zika virus - John England (USA)
• SS 21.2: Leprous neuropathies - Gerard Said (France)
• SS 21.3: Neuropathies in infectious diseases - Nazha Birouk (Morocco)
• SS 21.4: Infection related Neuromuscular disorders (Neuropathies and Myopathies) - Chandrashekhar Meshram (India)

Chair(s): Sonja Horn (Austria), Raad Shakir (UK)

• SS 22.1: The history of neuromuscular diseases and their treatment in Habsburg countries - Sonja Horn (Austria)
• SS 22.2: History on Myasthenia Gravis - Richard Barohn (USA)
• SS 22.3: Andalusian Neurology over 700 years - Raad Shakir (UK)

Chair(s): Richard Barohn (USA), Alexander Marx (Germany)

• SS 23.1: Overview of thymectomy in MG - Richard Barohn (USA)
• SS 23.2: Randomized controlled trial of thymectomy: a deeper dive into data - Gil Wolfe (USA)
• SS 23.3: Pathology of the thymus gland in MG - Alexander Marx (Germany)

Chair(s): Markus Rüegg (Switzerland), David Beeson (UK)

• WS 14.1: Molecular mechanisms affecting neuromuscular junction development and maintenance - Markus Rüegg (Switzerland)
• WS 14.2: Salbutamol and Dok-7 as potential treatment options for neuromuscular disorders - David Beeson (UK)
• WS 14.3: Sympathetic innervation of the neuromuscular junction; possible explanation for the therapeutic effect of sympathicomimetics in NMDs? - Rüdiger Rudolf (Germany)

Chair(s): Rolf Schröder (Germany), Gerhard Wiche (Austria)

• WS 15.1: Basics and what we are learning from mice - Gerhard Wiche (Austria)
• WS 15.2: Human plectin and clinical aspects - Rolf Schröder (Germany)
• WS 15.3: Plectin and mitochondria (mice and men) - Lilli Winter (Austria)
• WS 15.4: Plectin, cardiomyopathies, and therapeutic approaches (mice) - Oliver Müller (Germany)

Chair(s): Corrado Angelini (Italy), Kristl Claeys (Belgium)

• WS 16.1: The clinical phenotypes of calpainopathy - Andoni Urtizberea (France)
• WS 16.2: Muscle pathology of LGMD - Kristl Claeys (Belgium)
• WS 16.3: The advent of NGS in LGMD diagnosis - Vincenzo Nigro (Italy)
• WS 16.4: Perspectives in clinical trials of recessive and dominant LGMD - Corrado Angelini (Italy)

Chair(s): Andreas Steck (Switzerland), Hadi Manji (UK)

• WS 17.1: Vasculitic Neuropathies (Rheumatoid Disorders) - Gerard Said (France)
• WS 17.2: Statin Neuropathies - Hadi Manji (UK)
• WS 17.3: MGUS associated peripheral neuropathy: diagnosis and treatment - Andreas Steck (Switzerland)

Chair(s): David Beeson (UK), Fritz Zimprich (Austria)

• SS 24.1: Synaptic stability in CMS - David Beeson (UK)
• SS 24.2: Recent presynaptic CMS - Hanns Lochmüller (UK)
• SS 24.3: Clinical aspects of CMS - Hakan Cetin (Austria)
• SS 24.4: Treatment for CMS - Jacqueline Palace (UK)

Chair(s): Nils Erik Gilhus (Norway), Anna Punga (Sweden)

• WS 18.1: Autoantibodies in myasthenia gravis - Nils Erik Gilhus (Norway)
• WS 18.2: Micro-RNA as a biomarker in myasthenia gravis - Anna Punga (Sweden)
• WS 18.3: Thymus biomarkers and clinical relevance - Alexander Marx (Germany)

Chair(s): Monika Hofer (UK), Rolf Schröder (Germany)

• WS 19.2: Nerve biopsies - James Dyck (USA)
• WS 19.3: Skin biopsies - Giuseppe Lauria (Italy)
• WS 19.1: Muscle biopsies - Rolf Schröder (Germany) & Monika Hofer (UK)

Chair(s): Eva Feldman (USA), Brian Callaghan (USA)

• WS 20.1: Diabetic cranial neuropathies - Tudor Lupescu (Romania)
• WS 20.2: Musculoskeletal Complications of Diabetes are Common and Underdiagnosed - Anna Grisold (Austria)
• WS 20.3: Atypical Neuropathies in Diabetes: Diagnosis and Management - Amanda Peltier (USA)
• WS 20.4: Treatment Induced and Inflammatory Neuropathies in Diabetes - Brian Callaghan (USA)